Business
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission for CRB-601 is on-track for the first half of 2023Expanding immuno-oncology pipeline through strategic transactions remains key priorityCash and investments on hand of $86.8 million funds operations into the first quarter of 2024NORWOOD, Mass., May 10, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\"Corbus\" or the \"Company\"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.\n\n \n \n \n \n \n \n\n \nKey Corporate and Program Updates:\nAnti-integrin monoclonal antibodies (mAb) program targeting the inhibition of TGFβ is progressing on schedule.CRB-601, an anti-αvβ8 mAb, is being developed as a potential treatment for solid tumors. Corbus presented the first preclinical data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting in April 2022. The poster can be viewed at: www.corbuspharma.com/AACRposter.The most recent data from CRB-601 will be presented on May 11, 2022 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference. This new data demonstrates effects of CRB-601 in additional syngeneic animal models with increasing levels of resistance to check point inhibitors.Across models explored to date, CRB-601 demonstrates an enhancement of anti-tumor activity when combined with anti PD-1 therapy compared to either single agent alone. This enhancement of efficacy is associated with tumor infiltration of proliferating CD4+ and CD8+ T cells in addition to NK cells and M1 macrophages.Collectively, this data supports the hypothesis that blockade of local TGFb production by CRB-601 can lead to changes in immune cell infiltration in the tumor microenvironment, potentially enhancing the benefit of PD-1 blockade.IND-enabling activities for CRB-601 are ongoing and the program is on-schedule for an IND submission in the first half of 2023.A lead candidate, CRB-913, has been selected for the CB1 inverse agonist program. In animal models of diet-induced obesity, CRB-913 induced weight loss and impacted multiple metabolic parameters, both as monotherapy and in combination with semaglutide and tirzepatide. Corbus is seeking partnerships to advance ...